The Effect of Cytostatic Therapy on Cellular Immunity in vitro

  • M. Winnewisser
  • H. Theml
  • H. Begemann
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 52)


At a time when chemotherapy of tumors with combined cytostatic agents is becoming a routine treatment and the range of effectiveness of such therapy is becoming evident as an increasingly large number of patients is treated, we can turn our attention to the body’s own immunological surveillance and possible ways of influencing it. With this in mind, it is evident that the problems resulting from drug-induced suppression of cellular and humoral immunity must be taken into consideration as well as the positive therapeutic effect (i.e. tumor regression or stoppage of tumor growth). However, there are as yet no standardized methods for determining the degree of immunosuppression in man and thus facilitating the determination of dosage of the cytostatic agents.


Cytostatic Drug Cytostatic Agent Massive Dose Rebound Phenomenon Unknown Primary Tumor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    MILLS, J. A.: Immunol. 97, 239 (1966).Google Scholar
  2. 2.
    JANOSSY, G., GREAVES, M. F.: Clin. exp. Immun. 9, 483 (1971).PubMedGoogle Scholar
  3. 3.
    ROITT, J. M., GREAVES, M. F., TORRIGIANI, G., BROSTOFF, J., PLAYFAIR, J. H. L.: Lancet 1973 2, 1254.Google Scholar
  4. 4.
    BEGEMANN, H., THEML. H., WINNEWISSER, M.: Verh. dtsch. Ges. inn. Med. 78, 112 (1972).Google Scholar
  5. 5.
    FLAD, H. D., HOCHAPFEL, G., FLIEDNER, T. M., HEIMPEL, H.: Acta haemat. 44, 21 (1970).PubMedCrossRefGoogle Scholar
  6. 6.
    GARRIOCH, D. B., GOOD, R. A., GATTI, R. A.: Lancet 1971 1, 892.Google Scholar
  7. 7.
    NAGEL, G. A.: Schweiz, med. Wschr. 101, 13: 470 (1971).Google Scholar
  8. 8.
    HERSH, E. M., OPPENHEIM, J. J.: Cancer Res. 27, 98 (1967).PubMedGoogle Scholar
  9. 9.
    WATKINS, S. M.: Lancet 1973 2, 1254.CrossRefGoogle Scholar
  10. 10.
    MAKINODAN, T., SANTOS, G. W., QUINN, R. P.: Pharmacol. Res. 22, 189 (1970).Google Scholar
  11. 11.
    TALIAFERRO, W. H., TALIAFERRO, L. G.: J. infect. Dis. 95, 134 (1954).PubMedCrossRefGoogle Scholar
  12. 12.
    MERRIT, K., JOHNSON, A. G.: Proc. Soc. exp. Biol. (N. Y.) 115, 1132 (1964).Google Scholar
  13. 13.
    BORELLA, L., GREEN, A. A., WELSTER, R. G.: Blood 40, 47 (1972).Google Scholar
  14. 14.
    CHEEMA, A. R., HERSH, E. M.: Cancer 28, 851 (1971).PubMedCrossRefGoogle Scholar
  15. 15.
    WHITTAKER, M. G., REES, K., CLARK, C. G.: Lancet 1971 1, 892.PubMedCrossRefGoogle Scholar
  16. 16.
    SILK, M.: Cancer 20, 2088 (1967).PubMedCrossRefGoogle Scholar
  17. 17.
    SAMPLE, F. W., GERTNER, H. R., CHRETIEN, P. B.: J. nat. Cancer Inst. 46, 1291 (1971).PubMedGoogle Scholar
  18. 18.
    AL-SARRAF, M., VAITKEVIEINS, V. K.: Lancet 1971 2, 314.Google Scholar
  19. 19.
    KOHOUT, J., SCHNETZ, E.: Med. Klin. 2, 43 (1973).Google Scholar
  20. 20.
    STJERNSWÄRD, J.: J. nat. Cancer Inst. 40, 13 (1968).PubMedGoogle Scholar
  21. 21.
    KLEIN, G., SJÖGREN, H. O., KLEIN, E., HELLSTRÖM, K. E.: Cancer Res. 20, 1561 (1960).PubMedGoogle Scholar
  22. 22.
    STJERNSWÄRD, J., CLIFFORD, P., SING, S., SVEDMYR, E.: E. Afr. Med. J. 45, 7, 484 (1968).Google Scholar
  23. 23.
    MARROW, R. H., PIKE, M. C., KISIUDE, A.: Brit. med. J. 1967 4, 323.CrossRefGoogle Scholar
  24. 24.
    COOPER, H. L., RUBIN, A. D.: Science 152, 516 (1966).PubMedCrossRefGoogle Scholar
  25. 25.
    STJERNSWÄRD, A. J., ROWFOUD, G. F., LEE, M. R.: Lancet 1972 1, 687.Google Scholar
  26. 26.
    TREPEL, F.: In Der Lymphozyt, p. 127. Vienna: Pietschmann 1972.Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1975

Authors and Affiliations

  • M. Winnewisser
  • H. Theml
  • H. Begemann

There are no affiliations available

Personalised recommendations